Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07575399 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Name: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — clinical trial record (NCT07575399)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2026-05-11

View on ClinicalTrials.gov ↗

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Amendment history 3 changes detected by DataLookout

2026-07-03

Trial sites expanded: 40 → 43 locations

2026-06-12

Recruitment opened

2026-06-12

Trial sites expanded: 0 → 40 locations

Trial Details

NCT Number	NCT07575399
Lead Sponsor	Amgen
Conditions	Obesity or Overweight
Enrollment	300 participants
Start Date	2026-05-11
Primary Completion	2028-01-03 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-27